Oral Fampridine-SR Multiple Sclerosis Patients MS-F204
ID Number 07-0814Principal Investigator(s)
Department(s) or Division(s)
The objective of this study (MS-F204 EXT) is to evaluate the long-term safety, tolerability and activity of Fampridine -SR in subjects with multiple sclerosis who have previously participated in either an Acorda Therapeutics of Elan Corporation sponsored protocol.
Recruiting Patients: No